RxDoctor Payments Data

Samwel Oyugi, MD

Geriatric Medicine · Kingston, NYNPI 1952370678

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Johnson & Johnson at 34.0% of the total.

$1,489in general payments, 2019–2025

Across 62 payments — averaging $24.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$507
  • Pfizer$343
  • AbbVie$148
  • GSK$88
  • Abbott$87
  • Medtronic$83
  • plus $232 from 7 others

What the payments were for

  • Food & beverage$1,489100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,489 in reported general payments places this provider in the 85th percentile of 400 geriatric medicine providers in New York.

See all geriatric medicine providers in New York

Medicare billing

Part B allowed, 2024
$193,688
Medicare patients
540
Services billed
1,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,728
EliquisApixaban11$6,507
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav81$545
CefuroximeCefuroxime Axetil29$489
Pantoprazole Sodium33$337
Albuterol Sulfate HfaAlbuterol Sulfate12$264
Prednisone58$255
Carbidopa-LevodopaCarbidopa/Levodopa14$247
Nystatin13$219
Doxycycline Hyclate27$211
Tamsulosin Hcl24$163
Hydralazine Hcl17$160
Cefdinir13$128
Azithromycin21$85
Furosemide20$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$88$10,72817 claims
PfizerEliquis$343$6,50711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 geriatric medicine providers in New York.

Other geriatric medicine in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →